Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1306-1309

  Bhumbra, Nasreen A ^a   Sahloff, Eric G ^b   Oehrtman, Sandra J ^b   Horner, James M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Adrenal suppression; Drug interaction; Fluticasone; Lopinavir; Ritonavir

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOTROPIN; CYTOCHROME P450 3A4; DIDANOSINE; FLUTICASONE PROPIONATE; HYDROCORTISONE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MOMETASONE FUROATE; MONTELUKAST; PREDNISONE; PROTEINASE INHIBITOR;

ADRENAL SUPPRESSION; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CASE REPORT; COMORBIDITY; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; DRUG METABOLISM; ENZYME INHIBITION; HAIR GROWTH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; MALE; MOON FACE; NARANJO PROBABILITY SCALE; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SYMPTOMATOLOGY; WEIGHT GAIN;

ADMINISTRATION, INHALATION; ANDROSTADIENES; CHILD; CUSHING SYNDROME; DRUG THERAPY, COMBINATION; HUMANS; MALE; PYRIMIDINONES; RITONAVIR;

EID: 34547207106     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K075     Document Type: Article

References (18)

1. Hillebrand-Haverkort ME, Prummel MF, ten Veen JH. Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone (letter). AIDS 1999;13:1803.
2. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone (letter). Sex Trans Infect 1999;75:274.
3. Clevenburgh P, Corcostegui M, Gerard D, et al. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regime. J Infect 2002;44:194-5.
4. Gupta SK, Dube MP. Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 2002;35:e69-71.
5. Rouanet I, Peyrire H, Mauboussin JM, Vincent D. Cushing's syndrome in a patient treated by ritonavir Aopinavir and inhaled fluticasone. HIV Med 2003;4:149-50.
6. Nocent C, Raherison C, Dupon M, Taytard A. Unexpected effects of inhaled fluticasone in an HIV patient with asthma. J Asthma 2004;41:793-5.
7. Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone. AIDS 2005;19:740-1.
8. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005;90:4394-8.
9. Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J. Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction. Intern Med J 2005;35:67-72.
10. Johnson SR, Marion AA, Vrchoticky T, Emmanuel PJ, Lujan-Zilbermann J. Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr 2006;148:386-8.
11. Arrington-Sanders R, Hutton N, Siberry GK. Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J 2006;25:1044-8.
12. Centers for Disease Control and Prevention. 1994 Revised Classification System for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
13. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31.
14. National Asthma Education and Prevention Program: Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. www.nhlbi.nih.gov/guidelines/asthma/asthma-fullrpt.pdf (accessed 2007 Apr 2).
15. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone proprionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol 2001:51:103-5.
16. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159:941-55.
17. Daley-Yates PT, Kunka RL, Yin Y, Andrew SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004;60:265-8.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.